Balchem Corp. 10-Q Summary: Period Ended June 30, 2008
Business Context and Reporting Period
This is an unaudited Quarterly Report (Form 10-Q) for Balchem Corporation for the period ended June 30, 2008. Balchem develops, manufactures, and distributes specialty performance ingredients for the food, nutritional, pharmaceutical, animal health, and medical device sterilization industries. Effective March 31, 2008, the company realigned its reporting structure into three segments: Specialty Products; Food, Pharma & Nutrition; and Animal Nutrition & Health.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2008 | Six Months Ended June 30, 2007 |
|---|---|---|
| Net Sales | $119,762 | $71,970 |
| Gross Margin | $26,434 (22.1%) | $21,923 (30.5%) |
| Operating Income | $14,644 (12.2%) | $12,131 (16.9%) |
| Net Earnings | $9,365 | $7,506 |
| Diluted EPS | $0.50 | $0.41 |
| Cash from Operations | $8,539 | $2,242 |
| Cash and Equivalents (End of Period) | $2,642 | $5,312 |
| Total Debt (Current + Long-Term) | $24,036 | $28,177 |
| Working Capital | $22,882 | $16,139 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 66.4% year-over-year, driven primarily by the Animal Nutrition & Health segment, which grew 107.2% due to the full-year impact of the 2007 Chinook and Akzo Nobel acquisitions.
- Margin Compression: Operating margin decreased from 16.9% to 12.2%. This decline is attributed to the lower profit margins of the acquired businesses and rising petro-chemical raw material costs that could not be fully passed on to customers.
- Segment Performance:
- Specialty Products: Sales up 5.1%, but operating earnings down 10.7% due to raw material costs.
- Food, Pharma & Nutrition: Sales up 24.0%, with operating earnings surging 207.5% driven by pharmaceutical-grade calcium sales.
- Animal Nutrition & Health: Sales up 107.2%, with operating earnings up 19.3% despite raw material headwinds.
- Debt Reduction: Total debt decreased as the company made accelerated principal payments on the term loan used to fund the Chinook Acquisition.
Outlook, Risks, and Management Commentary
- Raw Material Volatility: Management notes the raw material environment remains unpredictable, specifically regarding petro-chemical inputs. The company is focusing on price increases and productivity improvements to mitigate these costs.
- Acquisition Strategy: The company is actively pursuing additional acquisition candidates and may seek additional bank loans or access to financial markets to fund them.
- Market Risks: The company has exposure to foreign currency exchange rates and commodity price risks. A 100 basis point change in interest rates would impact annual interest expense by approximately $240.
- Contingencies: The company is involved in ongoing environmental monitoring at its Slate Hill, NY site (costs <$5/year) and maintains indemnification for Superfund liabilities at its Verona, MO facility, which are the responsibility of the prior owner.
Investor Verification Checklist
- Verify the sustainability of the 66.4% revenue growth, noting that a significant portion is attributable to 2007 acquisitions rather than organic growth.
- Monitor the trajectory of petro-chemical raw material costs and the company's ability to implement price increases to restore operating margins.
- Review the debt repayment schedule, specifically the European Term Loan (maturing May 2010) and the U.S. Term Loan (maturing March 2010).
- Assess the impact of foreign currency fluctuations on the European operations (Akzo Nobel acquisition) given the reporting currency is USD.
- Confirm the status of the environmental remediation discussions with NYDEC regarding the Slate Hill site to ensure no unexpected liabilities arise.